Welcome to our dedicated page for EXPONENT SEC filings (Ticker: EXPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exponent Inc filings document operating results, Regulation FD disclosures, capital-return actions, and governance matters for a science and engineering consulting company. Recent Form 8-K reports record quarterly financial results, dividend declarations, and share repurchase authorizations tied to the company’s common stock.
Proxy materials cover shareholder voting matters, director elections, executive compensation, pay-versus-performance tables, and board governance. The filing record also includes material-event disclosures related to leadership and corporate governance, along with capital-structure disclosures relevant to Exponent’s public-company reporting.
EXPO submitted a Form 144 notice reporting a planned sale of 3,909 shares of Common Stock via exercise of stock options on 04/15/2026. The filing lists an associated cash figure of $264,052.95. It also discloses recent 10b5-1 sales: 3,912 shares on 03/16/2026 for $264,013.84 and 3,920 shares on 02/17/2026 for $263,239.62.
Exponent Inc. vice president John Pye received new stock option awards. On April 6, 2026, he was granted an Incentive Stock Option for 6,008 shares and a Non-Qualified Stock Option for 14,992 shares, each with an exercise price of $66.56 per share.
The options become exercisable in four equal annual installments and are scheduled to expire on April 6, 2036. These awards are compensation-related grants, not open-market purchases or sales, and increase his direct derivative exposure to Exponent common stock.
Exponent, Inc. announced a series of leadership changes, highlighted by the appointment of John D. Pye, Ph.D. as President and Eric Anderson as Chief Financial Officer, both effective May 1, 2026. Pye, a long‑tenured engineering leader at the firm, will receive a base salary of $650,000 and stock options for 21,000 shares vesting over four years. Anderson, who has led finance and accounting, will receive a $525,000 base salary and options for 12,600 shares, also vesting over four years.
Current CFO and Executive Vice President Richard L. Schlenker will cease serving as CFO on May 1, 2026 but remain Executive Vice President and has been nominated to stand for election to the Board of Directors. Paul R. Johnston, Ph.D., current Chairman and former CEO, will retire from the Board at the Annual Meeting of Stockholders on June 4, 2026, when Karen Richardson, now Lead Independent Director, will become Chairman of the Board. The company emphasizes continuity, noting there are no related‑party arrangements or family relationships involving the newly appointed executives.
The Vanguard Group filed Amendment No. 15 to a Schedule 13G/A reporting 0 shares of Exponent Inc. common stock. The filing states Vanguard underwent an internal realignment on January 12, 2026 and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.
The amendment lists amount beneficially owned: 0 and percent of class: 0%, and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Catherine Corrigan filed a Form 144 reporting a proposed sale of 3,912 shares of Common Stock via the exercise of stock options on 03/16/2026 for cash. The broker listed is Morgan Stanley Smith Barney LLC.
Prior 10b5-1 sales shown in the excerpt include 3,920 shares sold on 02/17/2026 for $263,239.62 and 1,663 shares sold on 01/15/2026 for $120,593.78.
SCHLENKER RICHARD L JR reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc. reported that EVP & Chief Financial Officer Richard L. Schlenker Jr. received a grant of 10,688 restricted stock units on March 13, 2026. Each unit represents a right to receive one share of common stock on a 1-for-1 basis. Following this compensation-related award, he holds 10,688 restricted stock units directly.
Sala Joseph reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc reported that Group Vice President Joseph Sala received a grant of 9,798 Restricted Stock Units on March 13, 2026. These RSUs are a form of stock-based compensation, with each unit convertible into one share of Exponent common stock on a 1-for-1 basis.
Following this award, Sala holds 9,798 RSUs directly, all tied to Exponent common stock. The grant was made at no cash cost per unit and reflects routine executive equity compensation rather than an open-market stock purchase or sale.
Exponent Inc reported that Group Vice President Maureen T. F. Reitman received a grant of 9,500 restricted stock units (RSUs) on March 13, 2026. Each RSU represents a right to receive one share of Exponent common stock, giving her 9,500 RSUs outstanding after this award. These units vest into common shares based on the company’s terms, with an exercise and expiration date in March 2030, and were granted at no cash cost to her as part of equity compensation.
Reiss Richard reported acquisition or exercise transactions in this Form 4 filing.
Exponent Inc reported that Group Vice President Richard Reiss received a grant of 2,970 restricted stock units on March 13, 2026. These RSUs represent the right to receive 2,970 shares of common stock on a 1-for-1 basis, as noted in the footnotes. Following this award, his reported derivative holdings in these RSUs total 2,970 units, reflecting routine equity-based compensation rather than any open-market buying or selling of shares.
Exponent Inc reported that Group Vice President Joseph Rakow received a grant of 10,688 restricted stock units on March 13, 2026. These RSUs represent a right to receive an equal number of shares of Exponent common stock on a 1-for-1 basis and are shown at a price of $0.00 because they are an equity award, not a market purchase. Following this grant, Rakow holds 10,688 RSUs directly, with an exercise and expiration date of March 13, 2030.